Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety & Immunogenicity of ChAdOx1 Chik & ChAdOx1 Zika Vaccines in Healthy Adults
NCT04440774Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Prophylactic Vaccines, Adenoviral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAdOx1 Chik and ChAdOx1 Zika in Chikungunya (CHIKV) and Zika virus disease, sponsored by University of Oxford. Primary endpoints: Occurrence of local reactogenicity signs and symptoms, Occurrence of solicited systemic reactogenicity signs and symptoms and 3 more. Started Oct 2020; status: completed.
02
Drugs
ChAdOx1 ChikChAdOx1 Zika
03
Conditions
Chikungunya (CHIKV)Zika virus disease
Beyond the preview
Go deeper on NCT04440774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440774.